SCOPUS 정보 검색 플랫폼

Volumn 5, Issue 3, 2010, Pages 183-191

Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: Current clinical status and perspectives

(3) Ronellenfitsch, Michael W a Steinbach, Joachim P a Wick, Wolfgang b

a UNIVERSITY HOSPITAL FRANKFURT (Germany)

b UNIVERSITY OF HEIDELBERG (Germany)

Author keywords

Clinical trials; Epidermal growth factor receptor; Glioblastoma; Malignant glioma; Mammalian target of rapamycin; Targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; AZD 8055; CARMUSTINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NIMOTUZUMAB; OSI 027; PHOSPHATIDYLINOSITOL 3 KINASE; PP 242; PROTEIN KINASE B; RAPAMYCIN; TEMOZOLOMIDE; TEMSIROLIMUS; TORIN 1; UNCLASSIFIED DRUG; XL 765;

CANCER CELL; CANCER RADIOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESEARCH; DRUG TARGETING; GENE ACTIVATION; GENE MUTATION; GLIOBLASTOMA; HUMAN; MOLECULAR BIOLOGY; OVERALL SURVIVAL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 78049274170 PISSN: 17762596 EISSN: 1776260X Source Type: Journal
DOI: 10.1007/s11523-010-0154-5 Document Type: Review

Times cited : (23)

References (70)

1
- 0034614637
- The hallmarks of cancer
- 1:CAS:528:DC%2BD3cXks1CktA%3D%3D 10.1016/S0092-8674(00)81683-9 10647931
- D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 1:CAS:528:DC%2BD3cXks1CktA%3D%3D 10.1016/S0092-8674(00)81683-9 10647931
- (2000) Cell , vol.100 , pp. 57-70
- Hanahan, D.¹ Weinberg, R.A.²

2
- 74549114727
- Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
- 1:CAS:528:DC%2BC3cXptVWisg%3D%3D 10.1111/j.1742-4658.2009.07448.x 19922469
- T Mitsudomi Y Yatabe 2010 Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer FEBS J 277 301 308 1:CAS:528: DC%2BC3cXptVWisg%3D%3D 10.1111/j.1742-4658.2009.07448.x 19922469
- (2010) FEBS J , vol.277 , pp. 301-308
- Mitsudomi, T.¹ Yatabe, Y.²

3
- 69949085814
- Cancer: The fat and the furious
- 1:CAS:528:DC%2BD1MXhtVygsbvK 10.1038/461044a 19727186
- E Gottlieb 2009 Cancer: the fat and the furious Nature 461 44 45 1:CAS:528:DC%2BD1MXhtVygsbvK 10.1038/461044a 19727186
- (2009) Nature , vol.461 , pp. 44-45
- Gottlieb, E.¹

4
- 0036591972
- Activation of GLUT1 by metabolic and osmotic stress: Potential involvement of AMP-activated protein kinase (AMPK)
- 1:CAS:528:DC%2BD38XltF2ksrk%3D 12006627
- K Barnes JC Ingram OH Porras LF Barros ER Hudson LG Fryer F Foufelle D Carling DG Hardie SA Baldwin 2002 Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK) J Cell Sci 115 2433 2442 1:CAS:528:DC%2BD38XltF2ksrk%3D 12006627
- (2002) J Cell Sci , vol.115 , pp. 2433-2442
- Barnes, K.¹ Ingram, J.C.² Porras, O.H.³ Barros, L.F.⁴ Hudson, E.R.⁵ Fryer, L.G.⁶ Foufelle, F.⁷ Carling, D.⁸ Hardie, D.G.⁹ Baldwin, S.A.¹⁰

5
- 0037275508
- Regulation of glucose transporter (GLUT1) gene expression by angiotensin II in mesangial cells: Involvement of HB-EGF and EGF receptor transactivation
- 1:CAS:528:DC%2BD3sXjtVelsr4%3D 10.1291/hypres.26.67 12661915
- A Nose Y Mori Y Uchiyama-Tanaka N Kishimoto K Maruyama H Matsubara T Iwasaka 2003 Regulation of glucose transporter (GLUT1) gene expression by angiotensin II in mesangial cells: involvement of HB-EGF and EGF receptor transactivation Hypertens Res 26 67 73 1:CAS:528:DC%2BD3sXjtVelsr4%3D 10.1291/hypres.26.67 12661915
- (2003) Hypertens Res , vol.26 , pp. 67-73
- Nose, A.¹ Mori, Y.² Uchiyama-Tanaka, Y.³ Kishimoto, N.⁴ Maruyama, K.⁵ Matsubara, H.⁶ Iwasaka, T.⁷

6
- 39449114808
- Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II
- DOI 10.1038/sj.cdd.4402285, PII 4402285
- S Miyamoto AN Murphy JH Brown 2008 Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II Cell Death Differ 15 521 529 1:CAS:528:DC%2BD1cXitVOlsLg%3D 10.1038/sj.cdd.4402285 18064042 (Pubitemid 351267303)
- (2008) Cell Death and Differentiation , vol.15 , Issue.3 , pp. 521-529
- Miyamoto, S.¹ Murphy, A.N.² Brown, J.H.³

7
- 70350418625
- MTOR signaling at a glance
- 1:CAS:528:DC%2BD1MXhsVKitrvP 10.1242/jcs.051011 19812304
- M Laplante DM Sabatini 2009 mTOR signaling at a glance J Cell Sci 122 3589 3594 1:CAS:528:DC%2BD1MXhsVKitrvP 10.1242/jcs.051011 19812304
- (2009) J Cell Sci , vol.122 , pp. 3589-3594
- Laplante, M.¹ Sabatini, D.M.²

8
- 67349217986
- Molecular mechanisms of mTOR-mediated translational control
- 10.1038/nrm2672 19339977
- XM Ma J Blenis 2009 Molecular mechanisms of mTOR-mediated translational control Nat Rev Mol Cell Biol 10 307 318 10.1038/nrm2672 19339977
- (2009) Nat Rev Mol Cell Biol , vol.10 , pp. 307-318
- Ma, X.M.¹ Blenis, J.²

9
- 32944457518
- MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
- DOI 10.1158/0008-5472.CAN-05-2925
- KE O'Reilly F Rojo QB She D Solit GB Mills D Smith H Lane F Hofmann DJ Hicklin DL Ludwig, et al. 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 1500 1508 10.1158/0008-5472.CAN-05-2925 16452206 (Pubitemid 43259931)
- (2006) Cancer Research , vol.66 , Issue.3 , pp. 1500-1508
- O'Reilly, K.E.¹ Rojo, F.² She, Q.-B.³ Solit, D.⁴ Mills, G.B.⁵ Smith, D.⁶ Lane, H.⁷ Hofmann, F.⁸ Hicklin, D.J.⁹ Ludwig, D.L.¹⁰ Baselga, J.¹¹ Rosen, N.¹²

10
- 23844438209
- Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
- DOI 10.1158/0008-5472.CAN-05-0917
- SY Sun LM Rosenberg X Wang Z Zhou P Yue H Fu FR Khuri 2005 Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition Cancer Res 65 7052 7058 1:CAS:528:DC%2BD2MXns1Wrt7c%3D 10.1158/0008-5472.CAN-05-0917 16103051 (Pubitemid 41161231)
- (2005) Cancer Research , vol.65 , Issue.16 , pp. 7052-7058
- Sun, S.-Y.¹ Rosenberg, L.M.² Wang, X.³ Zhou, Z.⁴ Yue, P.⁵ Fu, H.⁶ Khuri, F.R.⁷

11
- 38849208347
- Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma
- DOI 10.1371/journal.pmed.0050008
- TF Cloughesy K Yoshimoto P Nghiemphu K Brown J Dang S Zhu T Hsueh Y Chen W Wang D Youngkin, et al. 2008 Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma PLoS Med 5 e8 10.1371/journal.pmed.0050008 18215105 (Pubitemid 351198268)
- (2008) PLoS Medicine , vol.5 , Issue.1 , pp. 0139-0151
- Cloughesy, T.F.¹ Yoshimoto, K.² Nghiemphu, P.³ Brown, K.⁴ Dang, J.⁵ Zhu, S.⁶ Hsueh, T.⁷ Chen, Y.⁸ Wang, W.⁹ Youngkin, D.¹⁰ Liau, L.¹¹ Martin, N.¹² Becker, D.¹³ Bergsneider, M.¹⁴ Lai, A.¹⁵ Green, R.¹⁶ Oglesby, T.¹⁷ Koleto, M.¹⁸ Trent, J.¹⁹ Horvath, S.²⁰ more..

12
- 3342895823
- Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
- DOI 10.1016/j.cub.2004.06.054, PII S0960982204004713
- DD Sarbassov SM Ali DH Kim DA Guertin RR Latek H Erdjument-Bromage P Tempst DM Sabatini 2004 Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol 14 1296 1302 1:CAS:528:DC%2BD2cXmtVamsLs%3D 10.1016/j.cub.2004.06.054 15268862 (Pubitemid 38991819)
- (2004) Current Biology , vol.14 , Issue.14 , pp. 1296-1302
- Dos D. Sarbassov¹ Ali, S.M.² Kim, D.-H.³ Guertin, D.A.⁴ Latek, R.R.⁵ Erdjument-Bromage, H.⁶ Tempst, P.⁷ Sabatini, D.M.⁸

13
- 54549108740
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- Network TCGAR. 10.1038/nature07385
- Network TCGAR 2008 Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 1061 1068 10.1038/nature07385
- (2008) Nature , vol.455 , pp. 1061-1068

14
- 0030832167
- Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII
- 1:CAS:528:DyaK2sXmtFehtrs%3D 9307304
- CJ Wikstrand RE McLendon AH Friedman DD Bigner 1997 Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII Cancer Res 57 4130 4140 1:CAS:528:DyaK2sXmtFehtrs%3D 9307304
- (1997) Cancer Res , vol.57 , pp. 4130-4140
- Wikstrand, C.J.¹ McLendon, R.E.² Friedman, A.H.³ Bigner, D.D.⁴

15
- 7144227965
- Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
- DOI 10.1023/A:1008209720526
- BR Voldborg L Damstrup M Spang-Thomsen HS Poulsen 1997 Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials Ann Oncol 8 1197 1206 1:STN:280:DyaK1c7lslCluw%3D%3D 10.1023/A:1008209720526 9496384 (Pubitemid 28164074)
- (1997) Annals of Oncology , vol.8 , Issue.12 , pp. 1197-1206
- Rude Voldborg, B.¹ Damstrup, L.² Spang-Thomsen, M.³ Skovgaard Poulsen, H.⁴

16
- 33845926387
- Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain
- DOI 10.1371/journal.pmed.0030485
- JC Lee I Vivanco R Beroukhim JH Huang WL Feng RM DeBiasi K Yoshimoto JC King P Nghiemphu Y Yuza, et al. 2006 Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain PLoS Med 3 e485 10.1371/journal.pmed.0030485 17177598 (Pubitemid 46028511)
- (2006) PLoS Medicine , vol.3 , Issue.12 , pp. 2264-2273
- Lee, J.C.¹ Vivanco, I.² Beroukhim, R.³ Huang, J.H.Y.⁴ Feng, W.L.⁵ DeBiasi, R.M.⁶ Yoshimoto, K.⁷ King, J.C.⁸ Nghiemphu, P.⁹ Yuza, Y.¹⁰ Xu, Q.¹¹ Greulich, H.¹² Thomas, R.K.¹³ Paez, J.G.¹⁴ Peck, T.C.¹⁵ Linhart, D.J.¹⁶ Glatt, K.A.¹⁷ Getz, G.¹⁸ Onofrio, R.¹⁹ Ziaugra, L.²⁰ more..

17
- 0026521394
- Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails
- 1:CAS:528:DyaK38Xkt1Wntro%3D 10.1073/pnas.89.10.4309 1584765
- AJ Ekstrand N Sugawa CD James VP Collins 1992 Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails Proc Natl Acad Sci USA 89 4309 4313 1:CAS:528:DyaK38Xkt1Wntro%3D 10.1073/pnas.89.10.4309 1584765
- (1992) Proc Natl Acad Sci USA , vol.89 , pp. 4309-4313
- Ekstrand, A.J.¹ Sugawa, N.² James, C.D.³ Collins, V.P.⁴

18
- 60849115270
- IDH1 and IDH2 mutations in gliomas
- 1:CAS:528:DC%2BD1MXitFWru7o%3D 10.1056/NEJMoa0808710 19228619
- H Yan DW Parsons G Jin R McLendon BA Rasheed W Yuan I Kos I Batinic-Haberle S Jones GJ Riggins, et al. 2009 IDH1 and IDH2 mutations in gliomas N Engl J Med 360 765 773 1:CAS:528:DC%2BD1MXitFWru7o%3D 10.1056/NEJMoa0808710 19228619
- (2009) N Engl J Med , vol.360 , pp. 765-773
- Yan, H.¹ Parsons, D.W.² Jin, G.³ McLendon, R.⁴ Rasheed, B.A.⁵ Yuan, W.⁶ Kos, I.⁷ Batinic-Haberle, I.⁸ Jones, S.⁹ Riggins, G.J.¹⁰

19
- 0038615946
- Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo
- 1:CAS:528:DC%2BD3sXkt1aju7w%3D 12782577
- G Choe S Horvath TF Cloughesy K Crosby D Seligson A Palotie L Inge BL Smith CL Sawyers PS Mischel 2003 Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo Cancer Res 63 2742 2746 1:CAS:528:DC%2BD3sXkt1aju7w%3D 12782577
- (2003) Cancer Res , vol.63 , pp. 2742-2746
- Choe, G.¹ Horvath, S.² Cloughesy, T.F.³ Crosby, K.⁴ Seligson, D.⁵ Palotie, A.⁶ Inge, L.⁷ Smith, B.L.⁸ Sawyers, C.L.⁹ Mischel, P.S.¹⁰

20
- 33644820339
- Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
- DOI 10.1016/j.ccr.2006.02.019, PII S1535610806000560
- HS Phillips S Kharbanda R Chen WF Forrest RH Soriano TD Wu A Misra JM Nigro H Colman L Soroceanu, et al. 2006 Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 157 173 1:CAS:528: DC%2BD28XivFWjtL4%3D 10.1016/j.ccr.2006.02.019 16530701 (Pubitemid 43357943)
- (2006) Cancer Cell , vol.9 , Issue.3 , pp. 157-173
- Phillips, H.S.¹ Kharbanda, S.² Chen, R.³ Forrest, W.F.⁴ Soriano, R.H.⁵ Wu, T.D.⁶ Misra, A.⁷ Nigro, J.M.⁸ Colman, H.⁹ Soroceanu, L.¹⁰ Williams, P.M.¹¹ Modrusan, Z.¹² Feuerstein, B.G.¹³ Aldape, K.¹⁴

21
- 73649123907
- Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1
- 1:CAS:528:DC%2BC3cXkvFKgsL4%3D 10.1016/j.ccr.2009.12.020 20129251
- RG Verhaak KA Hoadley E Purdom V Wang Y Qi MD Wilkerson CR Miller L Ding T Golub JP Mesirov, et al. 2010 Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 98 110 1:CAS:528:DC%2BC3cXkvFKgsL4%3D 10.1016/j.ccr.2009.12.020 20129251
- (2010) Cancer Cell , vol.17 , pp. 98-110
- Verhaak, R.G.¹ Hoadley, K.A.² Purdom, E.³ Wang, V.⁴ Qi, Y.⁵ Wilkerson, M.D.⁶ Miller, C.R.⁷ Ding, L.⁸ Golub, T.⁹ Mesirov, J.P.¹⁰

22
- 0034899452
- Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor
- 1:CAS:528:DC%2BD3MXjtVOnsr4%3D 11297265
- G Lammering K Valerie PS Lin RB Mikkelsen JN Contessa JP Feden J Farnsworth P Dent RK Schmidt-Ullrich 2001 Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor Clin Cancer Res 7 682 690 1:CAS:528:DC%2BD3MXjtVOnsr4%3D 11297265
- (2001) Clin Cancer Res , vol.7 , pp. 682-690
- Lammering, G.¹ Valerie, K.² Lin, P.S.³ Mikkelsen, R.B.⁴ Contessa, J.N.⁵ Feden, J.P.⁶ Farnsworth, J.⁷ Dent, P.⁸ Schmidt-Ullrich, R.K.⁹

23
- 0032510679
- Drug resistance of human glioblastoma cells conferred by a tumor- specific mutant epidermal growth factor receptor through modulation of Bcl- X(L) and caspase-3-like proteases
- DOI 10.1073/pnas.95.10.5724
- M Nagane A Levitzki A Gazit WK Cavenee HJ Huang 1998 Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases Proc Natl Acad Sci USA 95 5724 5729 1:CAS:528:DyaK1cXjtFWku7k%3D 10.1073/pnas.95.10. 5724 9576951 (Pubitemid 28224163)
- (1998) Proceedings of the National Academy of Sciences of the United States of America , vol.95 , Issue.10 , pp. 5724-5729
- Nagane, M.¹ Levitzki, A.² Gazit, A.³ Cavenee, W.K.⁴ Huang, H.-J.S.⁵

24
- 0036132646
- CD95-mediated apoptosis of human glioma cells: Modulation by epidermal growth factor receptor activity
- 1:CAS:528:DC%2BD38XlvVSmtrk%3D 10.1111/j.1750-3639.2002.tb00418.x 11770895
- JP Steinbach P Supra HJ Huang WK Cavenee M Weller 2002 CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity Brain Pathol 12 12 20 1:CAS:528:DC%2BD38XlvVSmtrk%3D 10.1111/j.1750-3639.2002.tb00418.x 11770895
- (2002) Brain Pathol , vol.12 , pp. 12-20
- Steinbach, J.P.¹ Supra, P.² Huang, H.J.³ Cavenee, W.K.⁴ Weller, M.⁵

25
- 0037115523
- Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy
- 1:CAS:528:DC%2BD3sXhtV2jsA%3D%3D 12499272
- JS Eshleman BL Carlson AC Mladek BD Kastner KL Shide JN Sarkaria 2002 Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy Cancer Res 62 7291 7297 1:CAS:528: DC%2BD3sXhtV2jsA%3D%3D 12499272
- (2002) Cancer Res , vol.62 , pp. 7291-7297
- Eshleman, J.S.¹ Carlson, B.L.² Mladek, A.C.³ Kastner, B.D.⁴ Shide, K.L.⁵ Sarkaria, J.N.⁶

26
- 15244358389
- Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death
- DOI 10.1111/j.1471-4159.2004.02957.x
- JP Steinbach H Wolburg A Klumpp M Weller 2005 Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death J Neurochem 92 1340 1349 1:CAS:528:DC%2BD2MXislegsbk%3D 10.1111/j.1471-4159.2004.02957.x 15748153 (Pubitemid 40389204)
- (2005) Journal of Neurochemistry , vol.92 , Issue.6 , pp. 1340-1349
- Steinbach, J.P.¹ Wolburg, H.² Klumpp, A.³ Weller, M.⁴

27
- 1642360685
- Inhibition of Epidermal Growth Factor Receptor Signaling Protects Human Malignant Glioma Cells from Hypoxia-Induced Cell Death
- DOI 10.1158/0008-5472.CAN-03-3775
- JP Steinbach A Klumpp H Wolburg M Weller 2004 Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death Cancer Res 64 1575 1578 1:CAS:528: DC%2BD2cXhslektLk%3D 10.1158/0008-5472.CAN-03-3775 14996711 (Pubitemid 38428673)
- (2004) Cancer Research , vol.64 , Issue.5 , pp. 1575-1578
- Steinbach, J.P.¹ Klumpp, A.² Wolburg, H.³ Weller, M.⁴

28
- 67649411967
- Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death
- 10.1093/brain/awp093 19416948
- MW Ronellenfitsch DP Brucker MC Burger S Wolking F Tritschler J Rieger W Wick M Weller JP Steinbach 2009 Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death Brain 132 1509 1522 10.1093/brain/awp093 19416948
- (2009) Brain , vol.132 , pp. 1509-1522
- Ronellenfitsch, M.W.¹ Brucker, D.P.² Burger, M.C.³ Wolking, S.⁴ Tritschler, F.⁵ Rieger, J.⁶ Wick, W.⁷ Weller, M.⁸ Steinbach, J.P.⁹

29
- 77954382544
- Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients
- 1:CAS:528:DC%2BC3cXotlCnt78%3D 10.1007/s11060-009-0098-8 20035366
- J Rieger O Bähr K Müller K Franz J Steinbach E Hattingen 2010 Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients J Neurooncol 99 1 49 56 1:CAS:528:DC%2BC3cXotlCnt78%3D 10.1007/s11060-009-0098-8 20035366
- (2010) J Neurooncol , vol.99 , Issue.1 , pp. 49-56
- Rieger, J.¹ Bähr, O.² Müller, K.³ Franz, K.⁴ Steinbach, J.⁵ Hattingen, E.⁶

30
- 77957932346
- Bevacizumab-induced diffusion restriction in patients with glioma: Tumor progression or surrogate marker of hypoxia?
- 10.1200/JCO.2010.29.2029 20585096
- J Rieger O Bähr MW Ronellenfitsch J Steinbach E Hattingen 2010 Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia? J Clin Oncol 10.1200/JCO.2010.29. 2029 20585096
- (2010) J Clin Oncol
- Rieger, J.¹ Bähr, O.² Ronellenfitsch, M.W.³ Steinbach, J.⁴ Hattingen, E.⁵

31
- 34249779568
- Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
- DOI 10.1056/NEJMoa066838
- G Hudes M Carducci P Tomczak J Dutcher R Figlin A Kapoor E Staroslawska J Sosman D McDermott I Bodrogi, et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 1:CAS:528:DC%2BD2sXmtVKkurs%3D 10.1056/NEJMoa066838 17538086 (Pubitemid 46849157)
- (2007) New England Journal of Medicine , vol.356 , Issue.22 , pp. 2271-2281
- Hudes, G.¹ Carducci, M.² Tomczak, P.³ Dutcher, J.⁴ Figlin, R.⁵ Kapoor, A.⁶ Staroslawska, E.⁷ Sosman, J.⁸ McDermott, D.⁹ Bodrogi, I.¹⁰ Kovacevic, Z.¹¹ Lesovoy, V.¹² Schmidt-Wolf, I.G.H.¹³ Barbarash, O.¹⁴ Gokmen, E.¹⁵ O'Toole, T.¹⁶ Lustgarten, S.¹⁷ Moore, L.¹⁸ Motzer, R.J.¹⁹

32
- 68949102180
- Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
- 1:CAS:528:DC%2BD1MXhtFaitrrN 10.1200/JCO.2008.20.7977 19581539
- G Hess R Herbrecht J Romaguera G Verhoef M Crump C Gisselbrecht A Laurell F Offner A Strahs A Berkenblit, et al. 2009 Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 3822 3829 1:CAS:528:DC%2BD1MXhtFaitrrN 10.1200/JCO.2008.20.7977 19581539
- (2009) J Clin Oncol , vol.27 , pp. 3822-3829
- Hess, G.¹ Herbrecht, R.² Romaguera, J.³ Verhoef, G.⁴ Crump, M.⁵ Gisselbrecht, C.⁶ Laurell, A.⁷ Offner, F.⁸ Strahs, A.⁹ Berkenblit, A.¹⁰

33
- 67650088409
- Everolimus
- 1:CAS:528:DC%2BD1MXnvFans7s%3D 10.1038/nrd2924 19568281
- MB Atkins U Yasothan P Kirkpatrick 2009 Everolimus Nat Rev Drug Discov 8 535 536 1:CAS:528:DC%2BD1MXnvFans7s%3D 10.1038/nrd2924 19568281
- (2009) Nat Rev Drug Discov , vol.8 , pp. 535-536
- Atkins, M.B.¹ Yasothan, U.² Kirkpatrick, P.³

34
- 34547643764
- Temsirolimus
- DOI 10.1038/nrd2382, PII NRD2382
- B Rini S Kar P Kirkpatrick 2007 Temsirolimus Nat Rev Drug Discov 6 599 600 1:CAS:528:DC%2BD2sXotl2qtb8%3D 10.1038/nrd2382 (Pubitemid 47202485)
- (2007) Nature Reviews Drug Discovery , vol.6 , Issue.8 , pp. 599-600
- Rini, B.¹ Kar, S.² Kirkpatrick, P.³

35
- 62549160588
- First-in-class, first-in-human phase i results of targeted agents: Highlights of the 2008 American society of clinical oncology meeting
- 10.1186/1756-8722-1-20 18959794
- A Molckovsky LL Siu 2008 First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting J Hematol Oncol 1 20 10.1186/1756-8722-1-20 18959794
- (2008) J Hematol Oncol , vol.1 , pp. 20
- Molckovsky, A.¹ Siu, L.L.²

36
- 68149096799
- The pharmacology of mTOR inhibition
- DA Guertin DM Sabatini 2009 The pharmacology of mTOR inhibition Sci Signal pe2 24
- (2009) Sci Signal , vol.2 , pp. 24
- Guertin, D.A.¹ Sabatini, D.M.²

37
- 63749129788
- PI3K and mTOR inhibitors: A new generation of targeted anticancer agents
- 1:CAS:528:DC%2BD1MXksVClu78%3D 10.1016/j.ceb.2008.12.011 19201591
- S Brachmann C Fritsch SM Maira C Garcia-Echeverria 2009 PI3K and mTOR inhibitors: a new generation of targeted anticancer agents Curr Opin Cell Biol 21 194 198 1:CAS:528:DC%2BD1MXksVClu78%3D 10.1016/j.ceb.2008.12.011 19201591
- (2009) Curr Opin Cell Biol , vol.21 , pp. 194-198
- Brachmann, S.¹ Fritsch, C.² Maira, S.M.³ Garcia-Echeverria, C.⁴

38
- 69849112085
- Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
- 1:STN:280:DC%2BD1MrnsVGrtg%3D%3D 10.1093/annonc/mdp032 19491283
- B Neyns J Sadones E Joosens F Bouttens L Verbeke JF Baurain L D'Hondt T Strauven C Chaskis P In't Veld, et al. 2009 Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma Ann Oncol 20 1596 1603 1:STN:280:DC%2BD1MrnsVGrtg%3D%3D 10.1093/annonc/mdp032 19491283
- (2009) Ann Oncol , vol.20 , pp. 1596-1603
- Neyns, B.¹ Sadones, J.² Joosens, E.³ Bouttens, F.⁴ Verbeke, L.⁵ Baurain, J.F.⁶ D'Hondt, L.⁷ Strauven, T.⁸ Chaskis, C.⁹ In'T Veld, P.¹⁰

39
- 1842500007
- Phase II trial of gefitinib in recurrent glioblastoma
- DOI 10.1200/JCO.2004.08.110
- JN Rich DA Reardon T Peery JM Dowell JA Quinn KL Penne CJ Wikstrand LB Van Duyn JE Dancey RE McLendon, et al. 2004 Phase II trial of gefitinib in recurrent glioblastoma J Clin Oncol 22 133 142 1:CAS:528:DC%2BD2cXpsVKhsr8%3D 10.1200/JCO.2004.08.110 14638850 (Pubitemid 41095125)
- (2004) Journal of Clinical Oncology , vol.22 , Issue.1 , pp. 133-142
- Rich, J.N.¹ Reardon, D.A.² Peery, T.³ Dowell, J.M.⁴ Quinn, J.A.⁵ Penne, K.L.⁶ Wikstrand, C.J.⁷ Van Duyn, L.B.⁸ Dancey, J.E.⁹ McLendon, R.E.¹⁰ Kao, J.C.¹¹ Stenzel, T.T.¹² Rasheed, B.K.A.¹³ Tourt-Uhlig, S.E.¹⁴ Herndon II, J.E.¹⁵ Vredenburgh, J.J.¹⁶ Sampson, J.H.¹⁷ Friedman, A.H.¹⁸ Bigner, D.D.¹⁹ Friedman, H.S.²⁰ more..

40
- 62449150719
- Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
- 10.1200/JCO.2008.17.5984 19204207
- MJ van den Bent AA Brandes R Rampling MC Kouwenhoven JM Kros AF Carpentier PM Clement M Frenay M Campone JF Baurain, et al. 2009 Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 J Clin Oncol 27 1268 1274 10.1200/JCO.2008.17.5984 19204207
- (2009) J Clin Oncol , vol.27 , pp. 1268-1274
- Van Den Bent, M.J.¹ Brandes, A.A.² Rampling, R.³ Kouwenhoven, M.C.⁴ Kros, J.M.⁵ Carpentier, A.F.⁶ Clement, P.M.⁷ Frenay, M.⁸ Campone, M.⁹ Baurain, J.F.¹⁰

41
- 23944453425
- Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
- DOI 10.1200/JCO.2005.23.622
- E Galanis JC Buckner MJ Maurer JI Kreisberg K Ballman J Boni JM Peralba RB Jenkins SR Dakhil RF Morton, et al. 2005 Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study J Clin Oncol 23 5294 5304 1:CAS:528:DC%2BD2MXpslOrtLw%3D 10.1200/JCO.2005.23.622 15998902 (Pubitemid 46206983)
- (2005) Journal of Clinical Oncology , vol.23 , Issue.23 , pp. 5294-5304
- Galanis, E.¹ Buckner, J.C.² Maurer, M.J.³ Kreisberg, J.I.⁴ Ballman, K.⁵ Boni, J.⁶ Peralba, J.M.⁷ Jenkins, R.B.⁸ Dakhil, S.R.⁹ Morton, R.F.¹⁰ Jaeckle, K.A.¹¹ Scheithauer, B.W.¹² Dancey, J.¹³ Hidalgo, M.¹⁴ Walsh, D.J.¹⁵

42
- 0025281789
- Response criteria for phase II studies of supratentorial malignant glioma
- 1:STN:280:DyaK3c3ptlyitQ%3D%3D 2358840
- DR Macdonald TL Cascino SC Schold Jr JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 1:STN:280:DyaK3c3ptlyitQ%3D%3D 2358840
- (1990) J Clin Oncol , vol.8 , pp. 1277-1280
- MacDonald, D.R.¹ Cascino, T.L.² Schold Jr., S.C.³ Cairncross, J.G.⁴

43
- 21044431575
- Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
- DOI 10.1007/s10637-005-1444-0
- SM Chang P Wen T Cloughesy H Greenberg D Schiff C Conrad K Fink HI Robins L De Angelis J Raizer, et al. 2005 Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme Invest New Drugs 23 357 361 1:CAS:528:DC%2BD2MXmtVymtLY%3D 10.1007/s10637-005-1444-0 16012795 (Pubitemid 40980358)
- (2005) Investigational New Drugs , vol.23 , Issue.4 , pp. 357-361
- Chang, S.M.¹ Wen, P.² Cloughesy, T.³ Greenberg, H.⁴ Schiff, D.⁵ Conrad, C.⁶ Fink, K.⁷ Robins, H.I.⁸ De Angelis, L.⁹ Raizer, J.¹⁰ Hess, K.¹¹ Aldape, K.¹² Lamborn, K.R.¹³ Kuhn, J.¹⁴ Dancey, J.¹⁵ Prados, M.D.¹⁶

44
- 17944377486
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
- DOI 10.1073/pnas.171076798
- MS Neshat IK Mellinghoff C Tran B Stiles G Thomas R Petersen P Frost JJ Gibbons H Wu CL Sawyers 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci USA 98 10314 10319 1:CAS:528:DC%2BD3MXmvFWiurk%3D 10.1073/pnas.171076798 11504908 (Pubitemid 32803017)
- (2001) Proceedings of the National Academy of Sciences of the United States of America , vol.98 , Issue.18 , pp. 10314-10319
- Neshat, M.S.¹ Mellinghoff, I.K.² Tran, C.³ Stiles, B.⁴ Thomas, G.⁵ Petersen, R.⁶ Frost, P.⁷ Gibbons, J.J.⁸ Wu, H.⁹ Sawyers, C.L.¹⁰

45
- 17944368972
- +/- mice
- DOI 10.1073/pnas.171060098
- K Podsypanina RT Lee C Politis I Hennessy A Crane J Puc M Neshat H Wang L Yang J Gibbons, et al. 2001 An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice Proc Natl Acad Sci USA 98 10320 10325 1:CAS:528:DC%2BD3MXmvFWiurY%3D 10.1073/pnas.171060098 11504907 (Pubitemid 32803018)
- (2001) Proceedings of the National Academy of Sciences of the United States of America , vol.98 , Issue.18 , pp. 10320-10325
- Podsypanina, K.¹ Lee, R.T.² Politis, C.³ Hennessy, I.⁴ Crane, A.⁵ Puc, J.⁶ Neshat, M.⁷ Wang, H.⁸ Yang, L.⁹ Gibbons, J.¹⁰ Frost, P.¹¹ Dreisbach, V.¹² Blenis, J.¹³ Gaciong, Z.¹⁴ Fisher, P.¹⁵ Sawyers, C.¹⁶ Hedrick-Ellenson, L.¹⁷ Parsons, R.¹⁸

46
- 13944269599
- Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
- 1:CAS:528:DC%2BD2MXksFyqsA%3D%3D 15657358
- RK Goudar Q Shi MD Hjelmeland ST Keir RE McLendon CJ Wikstrand ED Reese CA Conrad P Traxler HA Lane, et al. 2005 Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition Mol Cancer Ther 4 101 112 1:CAS:528:DC%2BD2MXksFyqsA%3D%3D 15657358
- (2005) Mol Cancer Ther , vol.4 , pp. 101-112
- Goudar, R.K.¹ Shi, Q.² Hjelmeland, M.D.³ Keir, S.T.⁴ McLendon, R.E.⁵ Wikstrand, C.J.⁶ Reese, E.D.⁷ Conrad, C.A.⁸ Traxler, P.⁹ Lane, H.A.¹⁰

47
- 33746807790
- Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
- DOI 10.1212/01.wnl.0000223844.77636.29, PII 0000611420060711000038
- L Doherty DC Gigas S Kesari J Drappatz R Kim J Zimmerman L Ostrowsky PY Wen 2006 Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas Neurology 67 156 158 1:CAS:528:DC%2BD28XlvFylu7c%3D 10.1212/01.wnl.0000223844.77636.29 16832099 (Pubitemid 44305484)
- (2006) Neurology , vol.67 , Issue.1 , pp. 156-158
- Doherty, L.¹ Gigas, D.C.² Kesari, S.³ Drappatz, J.⁴ Kim, R.⁵ Zimmerman, J.⁶ Ostrowsky, L.⁷ Wen, P.Y.⁸

48
- 59349089499
- A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
- 1:CAS:528:DC%2BD1MXhtVGjtLY%3D 10.1007/s11060-008-9741-z 19018475
- TN Kreisl AB Lassman PS Mischel N Rosen HI Scher J Teruya-Feldstein D Shaffer E Lis LE Abrey 2009 A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) J Neurooncol 92 99 105 1:CAS:528:DC%2BD1MXhtVGjtLY%3D 10.1007/s11060-008-9741-z 19018475
- (2009) J Neurooncol , vol.92 , pp. 99-105
- Kreisl, T.N.¹ Lassman, A.B.² Mischel, P.S.³ Rosen, N.⁴ Scher, H.I.⁵ Teruya-Feldstein, J.⁶ Shaffer, D.⁷ Lis, E.⁸ Abrey, L.E.⁹

49
- 0034594628
- New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
- 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
- P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
- (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
- Therasse, P.¹ Arbuck, S.G.² Eisenhauer, E.A.³ Wanders, J.⁴ Kaplan, R.S.⁵ Rubinstein, L.⁶ Verweij, J.⁷ Van Glabbeke, M.⁸ Van Oosterom, A.T.⁹ Christian, M.C.¹⁰

50
- 72049118293
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02)
- SM Chang J Kuhn K Lamborn T Cloughesy I Robins F Lieberman A Yung J Dancey M Prados P Wen 2009 Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02) J Clin Oncol (Meeting Abstracts) 27 2004
- (2009) J Clin Oncol (Meeting Abstracts) , vol.27 , pp. 2004
- Chang, S.M.¹ Kuhn, J.² Lamborn, K.³ Cloughesy, T.⁴ Robins, I.⁵ Lieberman, F.⁶ Yung, A.⁷ Dancey, J.⁸ Prados, M.⁹ Wen, P.¹⁰

51
- 59149086517
- Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma
- 1:CAS:528:DC%2BD1MXivFyjurk%3D 10.1200/JCO.2008.18.9639 19075262
- MD Prados SM Chang N Butowski R DeBoer R Parvataneni H Carliner P Kabuubi J Ayers-Ringler J Rabbitt M Page, et al. 2009 Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma J Clin Oncol 27 579 584 1:CAS:528:DC%2BD1MXivFyjurk%3D 10.1200/JCO.2008.18.9639 19075262
- (2009) J Clin Oncol , vol.27 , pp. 579-584
- Prados, M.D.¹ Chang, S.M.² Butowski, N.³ Deboer, R.⁴ Parvataneni, R.⁵ Carliner, H.⁶ Kabuubi, P.⁷ Ayers-Ringler, J.⁸ Rabbitt, J.⁹ Page, M.¹⁰

52
- 72049118293
- Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02)
- PY Wen T Cloughesy J Kuhn K Lamborn LE Abrey F Lieberman HI Robins J Wright MD Prados M Gilbert 2009 Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02) J Clin Oncol (Meeting Abstracts) 27 2006
- (2009) J Clin Oncol (Meeting Abstracts) , vol.27 , pp. 2006
- Wen, P.Y.¹ Cloughesy, T.² Kuhn, J.³ Lamborn, K.⁴ Abrey, L.E.⁵ Lieberman, F.⁶ Robins, H.I.⁷ Wright, J.⁸ Prados, M.D.⁹ Gilbert, M.¹⁰

53
- 0026599333
- Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial
- 1:STN:280:DyaK38%2FnvVSnsg%3D%3D 1309204
- LW Brady C Miyamoto DV Woo M Rackover J Emrich H Bender S Dadparvar Z Steplewski H Koprowski P Black, et al. 1992 Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial Int J Radiat Oncol Biol Phys 22 225 230 1:STN:280:DyaK38%2FnvVSnsg%3D%3D 1309204
- (1992) Int J Radiat Oncol Biol Phys , vol.22 , pp. 225-230
- Brady, L.W.¹ Miyamoto, C.² Woo, D.V.³ Rackover, M.⁴ Emrich, J.⁵ Bender, H.⁶ Dadparvar, S.⁷ Steplewski, Z.⁸ Koprowski, H.⁹ Black, P.¹⁰

54
- 0036901175
- Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: Ten-year synopsis of a novel treatment
- DOI 10.1097/00000421-200212000-00001
- JG Emrich LW Brady TS Quang R Class C Miyamoto P Black U Rodeck 2002 Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment Am J Clin Oncol 25 541 546 10.1097/00000421-200212000-00001 12477994 (Pubitemid 35453655)
- (2002) American Journal of Clinical Oncology: Cancer Clinical Trials , vol.25 , Issue.6 , pp. 541-546
- Emrich, J.G.¹ Brady, L.W.² Quang, T.S.³ Class, R.⁴ Miyamoto, C.⁵ Black, P.⁶ Rodeck, U.⁷

55
- 57149118473
- Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177
- 1:CAS:528:DC%2BD1MXmsVSrsg%3D%3D 10.1200/JCO.2008.18.0612 18955445
- PD Brown S Krishnan JN Sarkaria W Wu KA Jaeckle JH Uhm FJ Geoffroy R Arusell G Kitange RB Jenkins, et al. 2008 Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177 J Clin Oncol 26 5603 5609 1:CAS:528:DC%2BD1MXmsVSrsg%3D%3D 10.1200/JCO.2008.18.0612 18955445
- (2008) J Clin Oncol , vol.26 , pp. 5603-5609
- Brown, P.D.¹ Krishnan, S.² Sarkaria, J.N.³ Wu, W.⁴ Jaeckle, K.A.⁵ Uhm, J.H.⁶ Geoffroy, F.J.⁷ Arusell, R.⁸ Kitange, G.⁹ Jenkins, R.B.¹⁰

56
- 20044366163
- Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
- DOI 10.1056/NEJMoa043330
- R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 1:CAS:528:DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330 15758009 (Pubitemid 40349501)
- (2005) New England Journal of Medicine , vol.352 , Issue.10 , pp. 987-996
- Stupp, R.¹ Mason, W.P.² Van Den Bent, M.J.³ Weller, M.⁴ Fisher, B.⁵ Taphoorn, M.J.B.⁶ Belanger, K.⁷ Brandes, A.A.⁸ Marosi, C.⁹ Bogdahn, U.¹⁰ Curschmann, J.¹¹ Janzer, R.C.¹² Ludwin, S.K.¹³ Gorlia, T.¹⁴ Allgeier, A.¹⁵ Lacombe, D.¹⁶ Cairncross, J.G.¹⁷ Eisenhauer, E.¹⁸ Mirimanoff, R.O.¹⁹

57
- 27744606737
- Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
- DOI 10.1056/NEJMoa051918
- IK Mellinghoff MY Wang I Vivanco DA Haas-Kogan S Zhu EQ Dia KV Lu K Yoshimoto JH Huang DJ Chute, et al. 2005 Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2012 2024 1:CAS:528:DC%2BD2MXht1SrtrrE 10.1056/NEJMoa051918 16282176 (Pubitemid 41609094)
- (2005) New England Journal of Medicine , vol.353 , Issue.19 , pp. 2012-2024
- Mellinghoff, I.K.¹ Wang, M.Y.² Vivanco, I.³ Haas-Kogan, D.A.⁴ Zhu, S.⁵ Dia, E.Q.⁶ Lu, K.V.⁷ Yoshimoto, K.⁸ Huang, J.H.Y.⁹ Chute, D.J.¹⁰ Riggs, B.L.¹¹ Horvath, S.¹² Liau, L.M.¹³ Cavenee, W.K.¹⁴ Nagesh Rao, P.¹⁵ Beroukhim, R.¹⁶ Peck, T.C.¹⁷ Lee, J.C.¹⁸ Sellers, W.R.¹⁹ Stokoe, D.²⁰ more..

58
- 21444450373
- Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
- DOI 10.1093/jnci/dji161
- DA Haas-Kogan MD Prados T Tihan DA Eberhard N Jelluma ND Arvold R Baumber KR Lamborn A Kapadia M Malec, et al. 2005 Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib J Natl Cancer Inst 97 880 887 1:CAS:528:DC%2BD2MXmtVahtrs%3D 10.1093/jnci/dji161 15956649 (Pubitemid 41417939)
- (2005) Journal of the National Cancer Institute , vol.97 , Issue.12 , pp. 880-887
- Haas-Kogan, D.A.¹ Prados, M.D.² Tihan, T.³ Eberhard, D.A.⁴ Jelluma, N.⁵ Arvold, N.D.⁶ Baumber, R.⁷ Lamborn, K.R.⁸ Kapadia, A.⁹ Malec, M.¹⁰ Berger, M.S.¹¹ Stokoe, D.¹²

59
- 27744506881
- Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium trials 01-03 and 00-01
- DOI 10.1158/1078-0432.CCR-05-0421
- AB Lassman MR Rossi JJ Raizer LE Abrey FS Lieberman CN Grefe K Lamborn W Pao AH Shih JG Kuhn, et al. 2005 Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 Clin Cancer Res 11 7841 7850 1:CAS:528:DC%2BD2MXhtF2isL%2FI 10.1158/1078-0432.CCR-05-0421 16278407 (Pubitemid 41611629)
- (2005) Clinical Cancer Research , vol.11 , Issue.21 , pp. 7841-7850
- Lassman, A.B.¹ Rossi, M.R.² Razier, J.R.³ Abrey, L.E.⁴ Lieberman, F.S.⁵ Grefe, C.N.⁶ Lamborn, K.⁷ Pao, W.⁸ Shih, A.H.⁹ Kuhn, J.G.¹⁰ Wilson, R.¹¹ Nowak, N.J.¹² Cowell, J.K.¹³ DeAngelis, L.M.¹⁴ Wen, P.¹⁵ Gilbert, M.R.¹⁶ Chang, S.¹⁷ Yung, W.A.¹⁸ Prados, M.¹⁹ Holland, E.C.²⁰ more..

60
- 65549145048
- An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1
- 1:CAS:528:DC%2BD1MXjtVSmtLY%3D 10.1074/jbc.M900301200 19150980
- CC Thoreen SA Kang JW Chang Q Liu J Zhang Y Gao LJ Reichling T Sim DM Sabatini NS Gray 2009 An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 J Biol Chem 284 8023 8032 1:CAS:528:DC%2BD1MXjtVSmtLY%3D 10.1074/jbc.M900301200 19150980
- (2009) J Biol Chem , vol.284 , pp. 8023-8032
- Thoreen, C.C.¹ Kang, S.A.² Chang, J.W.³ Liu, Q.⁴ Zhang, J.⁵ Gao, Y.⁶ Reichling, L.J.⁷ Sim, T.⁸ Sabatini, D.M.⁹ Gray, N.S.¹⁰

61
- 4344690193
- Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis
- DOI 10.1016/j.bbrc.2004.06.175, PII S0006291X04014688
- JP Steinbach C Eisenmann A Klumpp M Weller 2004 Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis Biochem Biophys Res Commun 321 524 530 1:CAS:528:DC%2BD2cXmt1Ogsrw%3D 10.1016/j.bbrc.2004.06.175 15358139 (Pubitemid 39118376)
- (2004) Biochemical and Biophysical Research Communications , vol.321 , Issue.3 , pp. 524-530
- Steinbach, J.P.¹ Eisenmann, C.² Klumpp, A.³ Weller, M.⁴

62
- 35348822482
- Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
- DOI 10.1126/science.1142946
- JM Stommel AC Kimmelman H Ying R Nabioullin AH Ponugoti R Wiedemeyer AH Stegh JE Bradner KL Ligon C Brennan, et al. 2007 Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies Science 318 287 290 1:CAS:528:DC%2BD2sXhtFCjt7vP 10.1126/science.1142946 17872411 (Pubitemid 47574858)
- (2007) Science , vol.318 , Issue.5848 , pp. 287-290
- Stommel, J.M.¹ Kimmelman, A.C.² Ying, H.³ Nabioullin, R.⁴ Ponugoti, A.H.⁵ Wiedemeyer, R.⁶ Stegh, A.H.⁷ Bradner, J.E.⁸ Ligon, K.L.⁹ Brennan, C.¹⁰ Chin, L.¹¹ DePinho, R.A.¹²

63
- 0025313141
- Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma
- DOI 10.1073/pnas.87.11.4207
- PA Humphrey AJ Wong B Vogelstein MR Zalutsky GN Fuller GE Archer HS Friedman MM Kwatra SH Bigner DD Bigner 1990 Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma Proc Natl Acad Sci USA 87 4207 4211 1:CAS:528:DyaK3cXltFensb0%3D 10.1073/pnas.87.11.4207 1693434 (Pubitemid 20218011)
- (1990) Proceedings of the National Academy of Sciences of the United States of America , vol.87 , Issue.11 , pp. 4207-4211
- Humphrey, P.A.¹ Wong, A.J.² Vogelstein, B.³ Zalutsky, M.R.⁴ Fuller, G.N.⁵ Archer, G.E.⁶ Friedman, H.S.⁷ Kwatra, M.M.⁸ Bigner, S.H.⁹ Bigner, D.D.¹⁰

64
- 70350236627
- An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
- 1:CAS:528:DC%2BD1MXht1CqtbfK 10.1158/1535-7163.MCT-09-0124 19825799
- JH Sampson GE Archer DA Mitchell AB Heimberger JE Herndon 2nd D Lally-Goss S McGehee-Norman A Paolino DA Reardon AH Friedman, et al. 2009 An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme Mol Cancer Ther 8 2773 2779 1:CAS:528:DC%2BD1MXht1CqtbfK 10.1158/1535-7163.MCT-09-0124 19825799
- (2009) Mol Cancer Ther , vol.8 , pp. 2773-2779
- Sampson, J.H.¹ Archer, G.E.² Mitchell, D.A.³ Heimberger, A.B.⁴ Herndon II, J.E.⁵ Lally-Goss, D.⁶ McGehee-Norman, S.⁷ Paolino, A.⁸ Reardon, D.A.⁹ Friedman, A.H.¹⁰

65
- 33947287270
- Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib
- DOI 10.1158/0008-5472.CAN-06-4293
- R Mulloy A Ferrand Y Kim R Sordella DW Bell DA Haber KS Anderson J Settleman 2007 Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib Cancer Res 67 2325 2330 1:CAS:528:DC%2BD2sXitlSjsLk%3D 10.1158/0008-5472.CAN-06- 4293 17332364 (Pubitemid 46424253)
- (2007) Cancer Research , vol.67 , Issue.5 , pp. 2325-2330
- Mulloy, R.¹ Ferrand, A.² Kim, Y.³ Sordella, R.⁴ Bell, D.W.⁵ Haber, D.A.⁶ Anderson, K.S.⁷ Settleman, J.⁸

66
- 2342471392
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib
- DOI 10.1056/NEJMoa040938
- TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan PL Harris SM Haserlat JG Supko FG Haluska, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 1:CAS:528: DC%2BD2cXktF2js7c%3D 10.1056/NEJMoa040938 15118073 (Pubitemid 38637993)
- (2004) New England Journal of Medicine , vol.350 , Issue.21 , pp. 2129-2139
- Lynch, T.J.¹ Bell, D.W.² Sordella, R.³ Gurubhagavatula, S.⁴ Okimoto, R.A.⁵ Brannigan, B.W.⁶ Harris, P.L.⁷ Haserlat, S.M.⁸ Supko, J.G.⁹ Haluska, F.G.¹⁰ Louis, D.N.¹¹ Christiani, D.C.¹² Settleman, J.¹³ Haber, D.A.¹⁴

67
- 4644238311
- EGFR mutations and sensitivity to gefitinib [3] (multiple letters)
- DOI 10.1056/NEJM200409163511221
- JN Rich BK Rasheed H Yan 2004 EGFR mutations and sensitivity to gefitinib N Engl J Med 351 1260 1261 1:CAS:528:DC%2BD2cXnslSjtrw%3D 10.1056/ NEJM200409163511221 15376352 author reply 1260-1261 (Pubitemid 39296317)
- (2004) New England Journal of Medicine , vol.351 , Issue.12 , pp. 1260-1261
- Sorscher, S.M.¹ Rich, J.N.² Rasheed, B.K.A.³ Yan, H.⁴ Rossi, G.⁵ Marchioni, A.⁶ Longo, L.⁷ Haber, D.A.⁸ Bell, D.W.⁹ Lynch, T.J.¹⁰

68
- 33846504444
- Compressing drug development timelines in oncology using phase '0' trials
- 1:CAS:528:DC%2BD2sXotFOjug%3D%3D 10.1038/nrc2066 17251919
- S Kummar R Kinders L Rubinstein RE Parchment AJ Murgo J Collins O Pickeral J Low SM Steinberg M Gutierrez, et al. 2007 Compressing drug development timelines in oncology using phase '0' trials Nat Rev Cancer 7 131 139 1:CAS:528:DC%2BD2sXotFOjug%3D%3D 10.1038/nrc2066 17251919
- (2007) Nat Rev Cancer , vol.7 , pp. 131-139
- Kummar, S.¹ Kinders, R.² Rubinstein, L.³ Parchment, R.E.⁴ Murgo, A.J.⁵ Collins, J.⁶ Pickeral, O.⁷ Low, J.⁸ Steinberg, S.M.⁹ Gutierrez, M.¹⁰

69
- 50349083186
- Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma
- 1:CAS:528:DC%2BD1cXmslygsbs%3D 10.1158/1078-0432.CCR-07-1824 18519772
- LH Wei H Su IJ Hildebrandt ME Phelps J Czernin WA Weber 2008 Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma Clin Cancer Res 14 3416 3426 1:CAS:528: DC%2BD1cXmslygsbs%3D 10.1158/1078-0432.CCR-07-1824 18519772
- (2008) Clin Cancer Res , vol.14 , pp. 3416-3426
- Wei, L.H.¹ Su, H.² Hildebrandt, I.J.³ Phelps, M.E.⁴ Czernin, J.⁵ Weber, W.A.⁶

70
- 0032767387
- Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
- 1:STN:280:DC%2BD3c%2FjtVSmsQ%3D%3D 10561324
- ET Wong KR Hess MJ Gleason KA Jaeckle AP Kyritsis MD Prados VA Levin WK Yung 1999 Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 2572 2578 1:STN:280: DC%2BD3c%2FjtVSmsQ%3D%3D 10561324
- (1999) J Clin Oncol , vol.17 , pp. 2572-2578
- Wong, E.T.¹ Hess, K.R.² Gleason, M.J.³ Jaeckle, K.A.⁴ Kyritsis, A.P.⁵ Prados, M.D.⁶ Levin, V.A.⁷ Yung, W.K.⁸

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.